Surveillance following radical or partial nephrectomy for renal cell carcinoma
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Renal cell carcinoma (RCC) is the most lethal of the common urologic malignancies, with approximately 40% of patients eventually dying of cancer progression. Approximately one third of patients present with metastatic disease and up to 50% treated for localized disease have a recurrence. Although the prognosis generally is poor in these patients, some may respond to immunotherapy and a subset of patients who develop solitary metastases can achieve long-term survival. Therefore, the timely identification of recurrences following surgical extirpation is imperative in the treatment of patients.
- Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29. CrossRef
- Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999, 83:18–29. CrossRef
- Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628–1631. CrossRef
- Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843–852. CrossRef
- Lam JS, Shvarts O, Figlin RA, Belldegrun AS: Renal cell carcinoma 2004: new frontiers in staging, prognostication, and targeted molecular therapy. J Urol 2005, in press. A comprehensive, state of the art review on the current concepts of staging, prognostication, and targeted molecular therapy for renal cell carcinoma.
- Sandock DS, Seftel AD, Resnick MI: A new protocol for the follow-up of renal cell carcinoma based on pathological stage. J Urol 1995, 154:28–31. CrossRef
- Levy DA, Slaton JW, Swanson DA, Dinney CP: Stage-specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998, 159:1163–1167. CrossRef
- Ljungberg B, Alamdari FI, Rasmuson T, Roos G: Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999, 84:405–411. CrossRef
- Hafez KS, Novick AC, Campbell SC: Patterns of tumor recurrence and guidelines for follow-up after nephronsparing surgery for sporadic renal cell carcinoma. J Urol 1997, 157:2067–2070. CrossRef
- Uzzo RG, Novick AC: Surveillance strategies following surgery for renal cell carcinoma. In Renal and Adrenal Tumors: Biology and Management. Edited by Belldegrun A, Ritchie AW, Figlin RA, et al. New York: Oxford University Press; 2003:324–330.
- Stephenson AJ, Chetner MP, Rourke K, et al.: Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 2004, 172:58–62. CrossRef
- Shvarts O, Lam JS, Pantuck AJ, et al.: Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. Submitted.
- Figlin RA: Renal cell carcinoma: management of advanced disease. J Urol 1999, 161:381–387. CrossRef
- Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408–417. CrossRef
- Kozlowski JM: Management of distant solitary recurrence in the patient with renal cancer contralateral kidney and other sites. Urol Clin North Am 1994, 21:601–624.
- Kavolius JP, Mastorakos DP, Pavlovich C, et al.: Resection of metastatic renal cell carcinoma. J Clin Oncol 1998, 16:2261–2266.
- Tanguay S, Pisters LL, Lawrence DD, Dinney CP: Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 1996, 155:26–29. CrossRef
- Esrig D, Ahlering TE, Lieskovsky G, Skinner DG: Experience with fossa recurrence of renal cell carcinoma. J Urol 1992, 147:1491–1494.
- Han KR, Pantuck AJ, Bui MH, et al.: Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003, 61:314–319. CrossRef
- Janzen NK, Laifer-Narin S, Han KR, et al.: Emerging technologies in uroradiologic imaging. Urol Oncol 2003, 21:317–326.
- Ramdave S, Thomas GW, Berlangieri SU, et al.: Clinical role of F-18 fluorodeoxyglucose positron-emission tomography for detection and management of renal cell carcinoma. J Urol 2001, 166:825–830. CrossRef
- Sandock DS, Seftel AD, Resnick MI: Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Urology 1997, 49:28–31. CrossRef
- Han KR, Bui MH, Pantuck AJ, et al.: TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 2003, 169:899–903. CrossRef
- Moinzadeh A, Libertino JA: Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 2004, 171:598–601. CrossRef
- Kim HL, Zisman A, Han KR, et al.: Prognostic significance of venous thrombus in renal cell carcinoma: Are renal vein and inferior vena cava involvement different? J Urol 2004, 171:588–591. CrossRef
- Patard JJ, Shvarts O, Lam JS, et al.: Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004, 171:2181–2185; quiz 2435. A retrospective analysis of 1454 patients undergoing partial or radical nephrectomy for T1N0M0 renal tumors from seven international academic centers that demonstrated no difference in cancer-specific survival or recurrence rates between patients undergoing partial or radical nephrectomy for renal tumors up to 7 cm. CrossRef
- Pantuck AJ, Zisman A, Dorey F, et al.: Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003, 169:2076–2083. CrossRef
- Pantuck AJ, Zisman A, Dorey F, et al.: Renal cell carcinoma with retroperitoneal lymph nodes: impact on survival and benefits of immunotherapy. Cancer 2003, 97:2995–3002. CrossRef
- Vasselli JR, Yang JC, Linehan WM, et al.: Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001, 166:68–72. CrossRef
- Terrone C, Guercio S, De Luca S, et al.: The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int 2003, 91:37–40. CrossRef
- Han KR, Bleumer I, Pantuck AJ, et al.: Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol 2003, 170:2221–2224. CrossRef
- Tsui KH, Shvarts O, Smith RB, et al.: Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000, 163:1090–1095; quiz 1295. CrossRef
- Bolkier M, Moskovitz B, Munichor M, et al.: Metastatic renal cell carcinoma to the bladder. Urol Int 1993, 50:101–103.
- Ovesen H, Gerstenberg T: Vaginal metastasis as the first sign of renal cell carcinoma: a case report and review of the literature. Scand J Urol Nephrol 1990, 24:237–238. CrossRef
- Fallick ML, Long JP, Ucci A: Metachronous renal cell carcinoma metastases to spermatic cord and penis. Scand J Urol Nephrol 1997, 31:299–300.
- Frank I, Blute ML, Cheville JC, et al.: An outcome-prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002, 168:2395–2400. CrossRef
- Shvarts O, Lam JS, Kim HL, et al.: Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol 2004, 172:867–870. A retrospective analysis of 1801 patients with clear cell RCC treated with radical nephrectomy in which an outcome-prediction model based on all available clinical and pathologic features significantly associated with death from RCC was generated. In patients with clear cell RCC, 1997 TNM stage, tumor size, nuclear grade, and histologic tumor necrosis were significantly associated with cancer-specific survival. CrossRef
- Itano NB, Blute ML, Spotts B, Zincke H: Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000, 164:322–325. CrossRef
- Steinbach F, Novick AC, Zincke H, et al.: Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J Urol 1995, 153:1812–1816. CrossRef
- Walther MM, Lubensky IA, Venzon D, et al.: Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma, and no renal disease: clinical implications. J Urol 1995, 154:2010–2015. CrossRef
- McNichols DW, Segura JW, De Weerd JH: Renal cell carcinoma: long-term survival and late recurrence. J Urol 1981, 126:17–23.
- Giuliani L, Giberti C, Martorana G, Rovida S: Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990, 143:468–473.
- Montie JE: Follow-up after partial or total nephrectomy for renal cell carcinoma. Urol Clin North Am 1994, 21:589–592.
- Kattan MW, Reuter V, Motzer RJ, et al.: A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001, 166:63–67. A retrospective analysis of 601 patients with RCC treated with nephrectomy. A postoperative nomogram combining various prognostic factors to predict the likelihood of recurrence after surgery for RCC was constructed. CrossRef
- Leibovich BC, Blute ML, Cheville JC, et al.: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663–1671. CrossRef
- Zisman A, Pantuck AJ, Dorey F, et al.: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649–1657. A retrospective analysis of 661 patients with RCC treated with nephrectomy. A novel integrated staging system was developed combining stage, grade, and Eastern Cooperative Oncology Group (ECOG) PS capable of stratifying the survival of RCC patients.
- Patard JJ, Kim HL, Lam JS, et al.: Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004, 22:3316–3322. An analysis of 4202 patients with RCC from eight international academic centers, which defines the general applicability of the University of California-Los Angeles staging system (UISS) for predicting survival in patients with RCC. CrossRef
- Zisman A, Pantuck AJ, Wieder J, et al.: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002, 20:4559–4566. This study describes a comprehensive algorithm that stratifies RCC patients into high-, intermediate-, and low-risk subgroups to predict postoperative patient outcomes and response to therapy. CrossRef
- Piltz S, Meimarakis G, Wichmann MW, et al.: Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002, 73:1082–1087. CrossRef
- Wronski M, Arbit E, Russo P, Galicich JH: Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 1996, 47:187–193. CrossRef
- Surveillance following radical or partial nephrectomy for renal cell carcinoma
Current Urology Reports
Volume 6, Issue 1 , pp 7-18
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links